Eylea (Aflibercept, BAY86-5321)

DRUG2 trials

Sponsors

Bayer

Conditions

Retinopathy of Prematurity (ROP)

Phase 3

Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy

CompletedNCT04004208

BayerRetinopathy of Prematurity (ROP)

Start: 2019-09-25End: 2021-02-12Updated: 2022-05-06

Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090

CompletedNCT04015180

BayerRetinopathy of Prematurity (ROP)

Start: 2020-03-18End: 2025-09-19Updated: 2025-10-10

Related Papers

Three-year Outcomes of Intravitreal Aflibercept versus Laser Therapy for Retinopathy of Prematurity.

2026-01-08

Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity

JAMA Network Open2024-04-3016 citations

Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study.

2024-01-104 citations

Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity

JAMA2022-07-26125 citations

Evaluation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) in a randomised controlled trial aiming for prevention of severe ROP: a substudy of the Mega Donna Mega trial

BMJ Open Ophthalmology2022-04-016 citations